Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 03'rd Aug 2022
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings
03:21pm, Tuesday, 02'nd Aug 2022
AxoGen is set to report Q2 FY22 earnings on Wednesday, following a period of flat performance on the chart. The company released top-line forecasts in its earnings pre-release from July, implying a pe
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
11:00am, Friday, 29'th Jul 2022 GlobeNewswire Inc.
ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
07:00am, Friday, 29'th Jul 2022
ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to
Read JMP Securities' Take On Axogen's Interim Update
07:26pm, Wednesday, 20'th Jul 2022 Benzinga
Axogen Inc (NASDAQ: AXGN) reported interim Q2 sales expectations of $34.4 million (+2% y/y; +8% excluding Avive sales in 2Q21) ahead of the consensus of ~$33.5 million.
JMP reiterated the Market O
Axogen, Inc. Appoints William Burke to Board of Directors
11:00am, Monday, 11'th Jul 2022 GlobeNewswire Inc.
Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Di
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
02:07pm, Monday, 09'th May 2022 Benzinga
Upgrades
For Axogen Inc (NASDAQ:AXGN), Canaccord Genuity upgraded the previous rating of Hold to Buy. Axogen earned $0.20 in the first quarter, compared to $0.08 in the year-ago quarter. The stock has
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2022 Results - Earnings Call Transcript
12:59pm, Saturday, 07'th May 2022
AxoGen, Inc. (NASDAQ:AXGN ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Eric
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Axogen Aces Phase 3 Study For Avance Nerve Graft
11:11am, Thursday, 05'th May 2022
Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries. Avance Nerve Graft is a biologically active o
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
11:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc Reports 2022 First Quarter Financial Results
08:05pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
11:00am, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
07:00am, Wednesday, 13'th Apr 2022
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Axogen, Inc. publishes inaugural ESG Report
11:00am, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries
